Antibody therapeutics: isotype and glycoform selection (Q36922260)

17 August 2017

1 reference

title

Antibody therapeutics: isotype and glycoform selection (English)

1 reference

17 August 2017

1 reference

Roy Jefferis

1

1 reference

PubMed ID

17727329

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

1401-1413

1 reference

17 August 2017

9

1 reference

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Upping the ante on antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Renaissance of cancer therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Human antibody-Fc receptor interactions illuminated by crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Interactions of immunoglobulins outside the antigen-combining site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Fcgamma receptors: old friends and new family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Glycosylation of recombinant antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Proteomic analysis of enriched microsomal fractions from GS-NS0 murine myeloma cells with varying secreted recombinant monoclonal antibody productivities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequentia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The therapeutic use of rituximab in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

21 January 2018

Human IgG Fc receptors

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Molecular basis of IgG subclass deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The structural requirements for complement activation by IgG: does it hinge on the hinge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

21 January 2018

IgG4 breaking the rules

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

The structure of a human type III Fcgamma receptor in complex with Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Production technologies for monoclonal antibodies and their fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Biopharmaceutical production in plants: problems, solutions and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Generation of Arabidopsis thaliana plants with complex N-glycans lacking beta1,2-linked xylose and core alpha1,3-linked fucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Isolation and analysis of a baculovirus vector that supports recombinant glycoprotein sialylation by SfSWT-1 cells cultured in serum-free medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Humanization of yeast to produce complex terminally sialylated glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Preparative expression of secreted proteins in bacteria: status report and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.9.1401

10.1517/14712598.7.9.1401

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17727329